7 news items
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
with benzyl alcohol-preserved drugs. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
16 Apr 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Mar 24
REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache
uqhfeyw2 2wrtq
RYTM
6 Mar 24
alcohol-preserved drugs. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin
vzdoldijbf3wuc5ih8mwdzk3i3dug9vy44oyjo9c8
RYTM
22 Feb 24
-capita incidence and prevalence of patients with hypothalamic obesity in Japan compared to the United States and Europe and no approved therapeutic options
- Prev
- 1
- Next